首页> 外文会议>Annual Meeting of the American Animal Hospital Association >CHRONIC MANAGEMENT OF PATIENTS WITH IMMUNE-MEDIATED BLOOD DISORDERS
【24h】

CHRONIC MANAGEMENT OF PATIENTS WITH IMMUNE-MEDIATED BLOOD DISORDERS

机译:免疫介导的血液障碍患者的慢性管理

获取原文

摘要

The cornerstone of the management of both immune-mediated heniolytic anemia (IMHA) and immune-mediated thrombocytopenia (IMT) is immunosuppressive therapy, particularly with glucocorticoids. The major mechanisms of immunosuppressive therapy are to decrease antibody synthesis, decrease the binding affinity between antibodies and blood cells, and decrease destruction of antibody-coated cells by the rnononuclear phagocytic system (MPS). However, even if antibody synthesis by plasma cells is arrested immediately, immunoglobulins may survive in the circulation for weeks; reduction of antibody synthesis is not an important part of initial IMHA/IMT treatment.
机译:治疗免疫介导的羊肝性贫血(IMHA)和免疫介导的血小板减少症(IMT)的基石是免疫抑制治疗,特别是糖皮质激素。免疫抑制治疗的主要机制是降低抗体合成,降低抗体和血细胞之间的结合亲和力,并通过rnononucol吞噬系统(MPS)降低抗体涂覆细胞的破坏。然而,即使血浆细胞的抗体合成立即被捕,即使立即被捕,免疫球蛋白也可能在血液循环中存活;减少抗体合成不是初始IMHA / IMT治疗的重要组成部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号